Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-04-08Clinical Trial Update: Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
A clinical trial investigating PET/CT as a predictor of neoadjuvant immunotherapy efficacy in non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer's post-marketing surveillance study of Zirabev to assess safety and effectiveness in domestic cancer patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-14Clinical Trial Update: Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation [Phase 1]
ClinicalTrials.gov entry indicates withdrawal of a Phase Ib study of furmonertinib in non-small cell lung cancer with EGFR exon 20 insertion…
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors [Phase 1, Phase 2]
ImmunityBio's QUILT-3.044 trial evaluating the NANT NSCLC vaccine in patients who progressed after PD-1/PD-L1 inhibitors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating NANT immunotherapy for resectable non-small cell lung cancer has been withdrawn from the study.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-02-07Clinical Trial Update: A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
Pfizer has withdrawn a clinical trial of dacomitnib for non-small cell lung cancer that has spread to the brain.
-
CLINICAL_TRIALS withdrawal · 2025-01-24Clinical Trial Update: Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers [Phase 1]
Phase 1 trial evaluating the combination of RMC-4630 and LY3214996 in metastatic KRAS-mutant cancers has been terminated. The study encompas…
-
EMA withdrawal · 2025-01-17EMA Withdrawn: Gavreto (pralsetinib) — Blueprint Medicines (Netherlands) B.V.
The EMA has withdrawn Gavreto (pralsetinib) from its marketing authorization; the decision was made on 17 July 2024 and relates to a previou…
-
CLINICAL_TRIALS withdrawal · 2025-01-15Clinical Trial Update: A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors [Phase 1]
A Phase 1 trial evaluating ASP1893 in adults with CLDN6-positive solid tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-12-20Clinical Trial Update: Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases [Phase 2]
A Phase 2 trial evaluating durvalumab with radiosurgery for brain metastases from non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-12-12Clinical Trial Update: Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC [NA]
The POIMS trial investigating pre-operative immuno-modulatory SBRT in early-stage non-small cell lung cancer has been withdrawn. The study i…
-
CLINICAL_TRIALS withdrawal · 2024-12-10Clinical Trial Update: Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). [Phase 2]
A phase 2 trial of Aumolertinib for EGFR-mutant resected non-small cell lung cancer (AERESA) was withdrawn, with no results reported.
-
CLINICAL_TRIALS withdrawal · 2024-12-10Clinical Trial Update: NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations. [Phase 2]
The Phase 2 neoadjuvant gefitinib trial for unresectable stage III non-small cell lung cancer with EGFR mutations has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-12-10Clinical Trial Update: APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC [Phase 2]
Phase 2 trial of Apatinib plus chemotherapy versus chemotherapy for first-line treatment of advanced non-small cell lung cancer has been wit…
-
CLINICAL_TRIALS withdrawal · 2024-12-09Clinical Trial Update: Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects [Phase 2]
Phase 2 trial of Vactosertib in combination with Pembrolizumab for PD-L1 positive non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-12-09Clinical Trial Update: Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System
The clinical trial evaluating markerless tracking SBRT for lung lesions on the VERO system has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-12-06Clinical Trial Update: Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. [Phase 2]
A Phase 2 neoadjuvant trial of JS001 alone or in combination with pemetrexed and carboplatin for resectable non-small cell lung cancer has b…
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…
-
CLINICAL_TRIALS withdrawal · 2024-11-20Clinical Trial Update: AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC [Phase 2]
Phase 2 trial evaluating the combination of sotorasib (AMG510) and lenvatinib in KRAS G12C-mutant metastatic non-small cell lung cancer has …
-
EMA withdrawal · 2024-11-06EMA Withdrawn: Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) — Sandoz GmbH
The European Medicines Agency has withdrawn Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) from the European market. It was indica…
-
EMA withdrawal · 2024-10-24EMA Withdrawn: Onbevzi (bevacizumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn the marketing authorization for Onbevzi (bevacizumab) by Samsung Bioepis NL B.V., across multiple cancer indications. …
-
CLINICAL_TRIALS withdrawal · 2024-10-23Clinical Trial Update: Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study [Phase 2]
The REPLACING Study, a Phase 2 trial evaluating robotic bronchoscopy with cone-beam CT and indocyanine green for removing lung lesions in St…
-
EMA withdrawal · 2024-10-17EMA Withdrawn: Gefitinib Mylan (gefitinib) — Mylan Pharmaceuticals Limited
The European Medicines Agency has withdrawn Gefitinib Mylan (gefitinib) from regulatory authorization. It was indicated for non-small cell l…
-
EMA withdrawal · 2024-10-17EMA Withdrawn: Ciambra (pemetrexed disodium hemipentahydrate) — Menarini International Operations Luxembourg S.A.
EMA withdrew Ciambra (pemetrexed disodium hemipentahydrate) from the European market on 17 August 2022, with indications for non-small cell …
-
CLINICAL_TRIALS withdrawal · 2024-10-08Clinical Trial Update: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating brigatinib after definitive chemoradiotherapy in ALK-rearranged stage III non-small cell lung cancer has been wit…